Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2017

Li Gang G, Somwar Romel, Joseph James, Smith Roger S, Hayashi Takuo, Martin Leenus, Franovic Aleksandra, Schairer Anni, Martin Eric, Riely Gregory J, Harris Jason, Yan Shunqi, Wei Ge, Oliver Jennifer W, Patel Rupal, Multani Pratik, Ladanyi Marc, Drilon Alexander

Abstract excerpt

Purpose: While multikinase inhibitors with RET activity are active in RET-rearranged thyroid and lung cancers, objective response rates are relatively low and toxicity can be substantial. The development of novel RET inhibitors with improved potency and/or reduced toxicity is thus an unmet need. RXDX-105 is a small molecule kinase inhibitor that potently inhibits RET. The purpose of the preclinical and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Neoplasm Proteins

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28011461
DOI: 10.1158/1078-0432.CCR-16-1887
PMCID: PMC5477238

Genes

RET
CCDC6
NCOA4
KDR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.PMID 28011461Read ↗

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Semantic proximity Read ↗

Selective RET kinase inhibition for patients with RET-altered cancers.Semantic proximity Read ↗

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsSemantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation.Semantic proximity Read ↗

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.Semantic proximity Read ↗

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Semantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

RET fusions observed in lung and colorectal cancers are sensitive to ponatinibSemantic proximity Read ↗

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.